PubMed Health⌕ Search

PubMed · 11921620

Epilepsy liaison nursing.

Abstract

The epilepsy liaison nurse's aim is to achieve a positive outcome in terms of clients' general well-being, social and physical activities, behavioural difficulties and other important issues in their lives. Many clients' problems stem from a lack of adequate information and support. A sound knowledge of the disorder can boost clients' and carers' confidence. They need information on what to do during a seizure, how to ensure that other people know what to do, and to understand the importance of being aware of precipitating factors. Clients and their families should also be encouraged to talk about the condition. This will reveal any misconceptions and anxieties and bring concerns into the open, helping to put them into perspective. Support for carers includes ensuring that clients have the personal care and support they need to improve or maintain a good quality of life. It is important that the person managing the client's epilepsy understands any issues related to learning disabilities and knows how to gain access to health and social care systems. By identifying and addressing the needs of clients and their families, epilepsy liaison nurses can make a positive difference to their lives.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Samuel Loughran, David O'Brien. Epilepsy liaison nursing.. https://pubmed.ncbi.nlm.nih.gov/11921620/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗